

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

<https://marketpublishers.com/r/E31C4567D3EEN.html>

Date: December 2017

Pages: 44

Price: US\$ 2,000.00 (Single User License)

ID: E31C4567D3EEN

Abstracts

Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape.

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with unabsorbed fat (steatorrhea), vitamin deficiencies, loss of appetite, and unexplained weight loss. Treatment includes pancreatic enzyme replacement therapy (PERT) and lifestyle modifications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of

key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively.

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Exocrine Pancreatic Insufficiency - Overview

Exocrine Pancreatic Insufficiency - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Exocrine Pancreatic Insufficiency - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development

Anthera Pharmaceuticals Inc

Celleron Therapeutics Ltd

Cilian AG

Laboratoires Mayoly Spindler SAS

Nordmark Arzneimittel GmbH & Co KG

Exocrine Pancreatic Insufficiency - Drug Profiles

lurlulipase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cilase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CXD-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

liprotamase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-1819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Exocrine Pancreatic Insufficiency - Dormant Projects

Exocrine Pancreatic Insufficiency - Discontinued Products

Exocrine Pancreatic Insufficiency - Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

Nov 09, 2017: Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura

Nov 02, 2017: Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference

Oct 20, 2017: AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier Submission

Sep 27, 2017: AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

Sep 07, 2017: Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis

Aug 23, 2017: AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

Aug 14, 2017: Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network

Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network

Jul 06, 2017: Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura

May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura

Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial

Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency

Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients

Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H2 2017

Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H2 2017

Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H2 2017

Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H2 2017

Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H2 2017

Exocrine Pancreatic Insufficiency - Dormant Projects, H2 2017

Exocrine Pancreatic Insufficiency - Discontinued Products, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Anthera Pharmaceuticals Inc

Celleron Therapeutics Ltd

Cilian AG

Laboratoires Mayoly Spindler SAS

Nordmark Arzneimittel GmbH & Co KG

I would like to order

Product name: Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/E31C4567D3EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E31C4567D3EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970